/publications/supplement/2012/Generic-Supplement-2012/Sandoz-Leading-the-Way-to-the-Generics-Market-of-the-Future-

Sandoz: Leading the Way to the Generics Market of the Future

Author:





Sandoz, the generics division of Novartis, is one of the 2 largest manufacturers of generic pharmaceuticals worldwide, and the global leader in complex, differentiated generics. With more than 24,000 employees in over 140 countries, our mission is to be the main provider of affordable, high-quality pharmaceuticals, helping secure long-term access to health care.

Sandoz develops, manufactures, and distributes a broad range of generic pharmaceuticals, with a focus on complex products such as biosimilars, generic injectables, anti-infectives, and ophthalmics, in each of which it holds the global #1 position. We believe that these types of products, which are difficult to develop, manufacture, and/or commercialize, increasingly represent the future of the generics industry. Following the $1.5 billion acquisition of Long Island–based Fougera in July 2012, Sandoz is also the US and global leader in generic dermatology medicines, another therapeutic area characterized by complex products.

As a division of the worldwide Novartis Group, whose products protected or treated more than 1.1 billion patients in 2011, Sandoz occupies a unique space in today’s industry. Overall, the Novartis portfolio includes patent-protected pharmaceuticals, generics, eyecare, over-the-counter medicines, vaccines, and diagnostics. As a Group, we see branded and generic pharmaceuticals as complementary, with generics driving competition and providing a catalyst for innovation.

Sandoz Inc, the US subsidiary of Sandoz and the largest country by sales, markets several hundred products across a broad range of therapeutic indications. It has led the US generics industry in terms of annual growth in the past few years and holds a top 3 position in the US market overall (#3 by dollar sales, IMS MAT through April 2012).

Sandoz products in the United States include enoxaparin sodium injection, launched in 2010 as the first generic version of Lovenox®, which recorded 2011 sales of more than USD 1 billion prior to the entry of generic competition, as well as Omnitrope®, the first recombinant somatropin follow-on biologic in the United States.

Based in Princeton, New Jersey, Sandoz Inc has manufacturing sites in Broomfield, Colorado, and Wilson, North Carolina, as well as a global Development center at East Hanover, New Jersey, focused on ensuring US first-to-file excellence. Following the acquisition of Fougera, the company has also created a global Center of Excellence for generic dermatology at Fougera’s 2 manufacturing sites in Melville and Hicksville, New York.

Together, we are proud to be leading the way to the generics industry of the future—and making Sandoz a “healthy decision” for the patients, customers, and health care professionals we serve.



For more information, visit www.us.sandoz.com.